Tildrakizumab Switching Study Shows Sustained Psoriasis Control
A 52-week prospective real-world study found that switching to tildrakizumab after anti-IL-17 failure led to sustained clinical improvement and quality ...
Tag: Anti-IL-17
POPULAR NEWS
-
Thicker Fetal Nuchal Translucency Linked to Higher Pregnancy Risks
-
CT Markers Show Most Reproducible Links to Death by Neurologic Criteria
-
Young Swiss Cancer Survivors Report Growth After Diagnosis, But Resilience Tells a Different Story
-
Transvalvular Leads Not Associated With Worse Tricuspid Repair Success in Selected Patients